eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
2/2022
vol. 9
 
Share:
Send email
Share:
abstract:
Special paper

Principles of management of severe asthma patients treated with systemic glucocorticosteroids – Experts’ recommendations on dose reduction and discontinuation of these drugs

Aleksandra Kucharczyk
1
,
Lucyna Bednarek-Papierska
2
,
Adam Barczyk
3
,
Piotr Kuna
4
,
Marita Nittner-Marszalska
5
,
Andrzej Obojski
5
,
Paweł Śliwiński
6
,
Maciej Kupczyk
7

  1. Klinika Chorób Wewnętrznych, Pneumonologii, Alergologii i Immunologii Klinicznej, Wojskowy Instytut Medyczny Ministerstwa Obrony Narodowej, Warszawa, Polska
  2. Klinika Endokrynologii, Centrum Medycznego Kształcenia Podyplomowego, Warszawa, Polska
  3. Katedra i Klinika Pneumonologii, Wydział Lekarski, Śląski Uniwersytet Medyczny, Katowice, Polska
  4. Klinika Chorób Wewnętrznych, Astmy i Alergii, Uniwersytet Medyczny, Łódź, Polska
  5. Katedra i Klinika Chorób Wewnętrznych, Pneumonologii i Alergologii, Uniwersytet Medyczny im. Piastów Śląskich, Wrocław, Polska
  6. Instytut Gruźlicy i Chorób Płuc, II Klinika Chorób Płuc, Warszawa, Polska
  7. Oddział Kliniczny Chorób Wewnętrznych, Astmy i Alergii z Odcinkiem dla Dzieci, Uniwersytecki Szpital Kliniczny nr 1 im. N. Barlickiego, Łódź, Polska
Alergologia Polska – Polish Journal of Allergology 2022; 9, 2: 70–77
DOI: https://doi.org/10.5114/pja.2022.116292
Online publish date: 2022/05/17
View full text Get citation
 
PlumX metrics:
According to GINA guidelines chronic therapy with oral glucocorticosteroids in patients with severe asthma must be limited to those who have been excluded from biological therapies, and other interventions have proved unsuccessful, as the use of even single doses of systemic glucocorticosteroids is associated with the risk of severe side effects. Therefore, optimal asthma control should be pursued in all cases, and each patient must be monitored for the number of exacerbations and the use of systemic corticosteroids. This will allow the identification of patients who are not optimally treated, who should be referred to specialist centers in order to deepen the differential diagnosis and possibly initiate biological therapy. In most patients, this enables a reduction in the number of exacerbations, as well as a significant dose reduction or withdrawal of long-term oral glucocorticosteroids, the use of which should be significantly limited due to numerous side effects. Discontinuation of oral glucocorticosteroids is a major problem, as symptoms of adrenal insufficiency develop in more than half of patients after prolonged use of these drugs. These are the first recommendations regarding the proposed diagnostic and therapeutic management in this group of patients.
keywords:

severe asthma, systemic glucocorticosteroids, oral glucocorticosteroids, biologics


Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.